Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 88% demonstrate that CR at 180 days, 69% at 270 days

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon May 30, 2022 10:02pm

404 Views

Post# 34718782

RE:RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days

Enrique, I am very encouraged. What would really get me going is if we start to see some PR after first dose convert to CR after second dose. THAT would be huge! IMO... It would show the market that trying 1433 again is a great idea if it doesn't work the first time.

enriquesuave wrote:
Actually numbers were better for evaluable patients at 180 days (50% CR)vs (46% CR)at 90 days. That is 109% (not 88%). They are being conservative. That is why I'm waiting to see numbers at 270 days which could foretell 360 and 450 days on Optimized patients. 270 days is steady at 39% CR meaning no new data in last month. Next update will show what a second treatment can do in Optimized patients who were NR or PR at 180 days. In the new MD& A released today, the 1st 20 patients chart with all assessments completed shows very good numbers and these include the 1st 12 non-Optimized. If BTD is granted, which it definitely should IMO, and we show consistent data or even better, on a few more patients ( all Optimized) , then AA is next. IMHO.

FGPstock wrote:

I think you guys may be reading this statement wrong. 46% were CR after 90 days. then 88% of the 46% were still CR after 180.

Not sure how the PR factors in

For all Evaluable Patients, who achieved a CR at 90 days, 88% demonstrate that CR at 180 days, 69% at 270 days, 50% at 360 days and 56% at 450 days, demonstrating a strong duration of complete response.